ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) — ConTTRibute

ATTR Amyloidosis Clinical Trial

Official title:
ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to: - Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients - Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting - Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Amyloidosis
ATTR Amyloidosis
Transthyretin-Mediated Amyloidosis

Clinical Trial Details

NCT number	NCT04561518
Study type	Observational
Source	Alnylam Pharmaceuticals
Contact	Alnylam Clinical Trial Information Line
Phone	1-877-ALNYLAM
Email	clinicaltrials@alnylam.com
Status	Recruiting
Phase
Start date	November 23, 2020
Completion date	September 2030

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02595983` - The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant	Phase 2
Recruiting	`NCT05444920` - The Italian Transthyretin Amyloidosis Web-Network
Recruiting	`NCT05184088` - Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis	Phase 3
Recruiting	`NCT06367842` - Orthopaedic Specimen Pathology and Early Diagnosis of ATTR Cardiopathy (ATTR-ORTHO)
Recruiting	`NCT06355934` - OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis